TIDMSLN

RNS Number : 4344H

Silence Therapeutics PLC

03 December 2020

Director Dealing

3(rd) December 2020

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that, on the 30th November 2020 and 1(st) December 2020, 4,700 and 1,000 American Depositary Shares ("ADSs") respectively were purchased by Mark Rothera, Chief Executive Officer of the Company, at $18.20 per ADS. Each ADS is a tradeable security representing 3 of the Company's Ordinary Shares

Following this purchase, Mark Rothera is interested in 5,700 ADSs representing 17,100 ordinary shares (0.02%) of the issued share capital of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial responsibilities 
       (PDMR) / person closely associated 
 a)   Name                         Mark Rothera 
     ---------------------------  ---------------------------------------------- 
 2.   Reason for the notification 
     --------------------------------------------------------------------------- 
 a)   Position / status            Chief Executive Officer 
     ---------------------------  ---------------------------------------------- 
 b)   Initial notification         Initial notification 
       / Amendment 
     ---------------------------  ---------------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     --------------------------------------------------------------------------- 
 a)   Name                         Silence Therapeutics plc 
     ---------------------------  ---------------------------------------------- 
 b)   LEI                          213800SSURRJBX85SQ91 
     ---------------------------  ---------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     --------------------------------------------------------------------------- 
 a)   Description of               American Depositary Shares (ADS), each 
       the financial instrument,    of which represents three (3) Ordinary 
       type of instrument           Shares of 5 pence each in the capital 
                                    of Silence Therapeutics plc 
       Identification 
       code 
 
                                    ISIN US82686Q1013 
     ---------------------------  ---------------------------------------------- 
 b)   Nature of the transaction    Purchase of Silence Therapeutics plc ADS 
     ---------------------------  ---------------------------------------------- 
 c)   Prices(a) and volume(s)        Price(s)   Volume(s) 
                                      $17.98     1200 ADSs 
                                                ---------- 
                                      $17.99     500 ADSs 
                                                ---------- 
                                      $18.99     800 ADSs 
                                                ---------- 
                                      $18.35     200 ADSs 
                                                ---------- 
                                      $18.00     2000 ADSs 
                                                ---------- 
                                      $18.30     1000 ADSs 
                                                ---------- 
     ---------------------------  ---------------------------------------------- 
 d)   Aggregated information       Aggregate Volume: 5,700 ADSs 
       - Aggregated volume          Metric for Quantity: ADSs 
       - Price                      Aggregated Volume Price per ADS: $18.20 
     ---------------------------  ---------------------------------------------- 
 e)   Date of the transaction      30 November 2020 (Time zone: Eastern Standard 
                                    Time) 
                                    1 December 2020 (Time zone: Eastern Standard 
                                    Time) 
     ---------------------------  ---------------------------------------------- 
 f)   Place of the transaction     Nasdaq Capital Market 
     ---------------------------  ---------------------------------------------- 
 

Enquiries:

 
 Silence Therapeutics plc                              Tel: +1 (646) 637-3208 
  Gem Hopkins, Head of IR & Corporate Communications 
  Investec Bank plc (Nominated Adviser and              Tel: +44 (0) 20 
   Broker)                                               7597 5970 
   Daniel Adams/Gary Clarence 
 European IR                                           Tel: +44 (0) 20 
  Consilium Strategic Communications                    3709 5700 
  Mary-Jane Elliott/Chris Welsh/Angela Gray 
  silencetherapeutics@consilium-comms.com 
 US IR                                                  Tel: +1 (443) 213-0505 
  Westwicke Partners 
  Peter Vozzo 
  peter.vozzo@westwicke.com 
 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGCBDDGSGDGGX

(END) Dow Jones Newswires

December 03, 2020 04:44 ET (09:44 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Silence Therapeutics Charts.
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Silence Therapeutics Charts.